Voluminous and Vesicular: Diffuse Large B Cell Lymphoma (DLBCL)

Anubha Bajaj*

AB Diagnostics, Hospital and Health Care, West Delhi, Delhi, India

Abstract

Previously chronicled as “Old histiocytic sarcoma” or “Old reticulum cell sarcoma”, Diffuse Large B Cell Lymphoma (DLBCL) is a composite and aggressive non-hodgkin’s lymphoma. An estimated 40% of lymphomas with multi-various disorders comprise the High-Grade B Cell Lymphoma (HGBCL). The mean age of detection may be at 60 years. Extra nodal and DLBCL comprise 40% instances with a half (50%) depicting progressive disease. The World Health Organization (WHO) categorization highlights the specific molecular attributes of the lymphoma such as the genomic rearrangements of the MYC and BCL2 and/or BCL6. Co-existent genetic anomalies may define the aggressive “Double Hit (DH) lymphoma” with a poor prognosis, initially scripted in 1988. DLBCL may emerge in the South Asian continent with the prevalence identical to that of the developed world (30%-40%), though the incidence of the disorder may be enhanced in the Asian countries (60%-70%). The majority (>80%) of the individuals with an aggressive B Cell Double Hit Lymphoma (HGBCL DH) may elucidate concomitant translocations in the MYC and BCL2 genes. The remainder (20%) of the persons may depict concordant MYC and BCL6 translocations along with the enumeration of the BCL2 gene with an absence of the BCL2 translocation which may not influence the disease outcome. The Double Expresser Lymphomas (DE DLBCL), as exemplified by the co-existent MYC and BCL2, may depict a poor outcome, although superior to the “Double Hits (DHs)”. The DE DLBCL may be incorporated as the DLBCL Not Otherwise Specified (DLBCL NOS) by the WHO.

Keywords: B cell lymphoma; Tumour; Ufemation; Immune phenotypic markers; Carcinoma; Malignant melanoma; Oncogene

Abbreviations: DLBCL: Diffuse Large B Cell Lymphoma; HGBCL: High Grade B Cell Lymphoma; WHO: World Health Organization; DH: Double Hit; DE: Double Expresser; CSR: Class Switch Recombination; PS: Performance Status; IPI: International Prognostic Index; LDH: Lactic Dehydrogenase; BL: Burkitt’s Lymphoma; GCB: Germinal Centre B cell; CNS: Central Nervous System; ABC: Activated B Cell; PFS: Progression Free Survival; OS: Overall Survival; ASCT: Autologous Stem Cell Transplant; Ig: Immunoglobulin

Introduction

Morphological elucidation

Adults may be preponderantly affected, though children may not be exempt. The preliminary disease may be limited. Enhanced extra-nodal manifestation, a rapid evolution, and an unfavorable prognosis signify the disorder. Bone marrow and hepatic involvement may be minimal, in contrast to the follicular lymphomas or small lymphocytic lymphomas. An estimated half (40%) of the disorder may be situated on one side of the diaphragm with extra nodal representation as in the Gastro-Intestinal Tract (GIT), skin or skeletal system [1-3]. Massive, disseminated nodules may exemplify the hepato-splenic involvement. Enormous, homogenized, implicated lymph nodes may display minimal necrosis. A diffuse nodal configuration with the complete or partial obliterated architecture may be characteristic. The tumour cell may ingress the inter-follicular or sinusal regions. Enlarged cells with abundant cytoplasm, vesicular nuclei and conspicuous nucleoli may be demonstrated with the immune phenotypic markers of a B cell lineage. Predominant sclerosis may co-exist with frequent extra-nodal tumefaction. Innumerable mitosis may elucidate a focal starry sky pattern [3,4].

Cytological categorization

Centroblastic variant: A tumour may represent an aggressive and diffuse analogue of the large cell follicular lymphoma (grade 3). Commingled quantities of cleaved and non-cleaved large cells may be visualized. The non-cleaved variant may be mistaken for an immunoblastic lymphoma. The faint cytoplasm with reduced pyroninophilia, marginal nucleoli, a lack of plasmacytoid differentiation, inter-mingled small and large cleaved cells with a co-existent follicular lymphoma may produce the distinction [3].

Immunoblastic variant: An immunoblastic characterization of the cells with an amplified vesicular nucleus, preponderant centric nucleolus with a dense nuclear membrane, a darkly stained amorphophilic or pyroninophilic cytoplasm with an obvious nuclear hof may be delineated with the frequent variant. Bi-nucleation or multi-nucleation may elucidate Reed Sternberg like cells or may simulate plasma cells (cartwheel chromatin, increased peri-nuclear hof) [5,6]. Immune peroxidase staining may depict intra-cytoplasmic Immunoglobulin (Ig). The particular subtype may appear with the natural immune deficiency, immune suppression, immune proliferative conditions such as the Angio-Immunoblastic Lympho Proliferative Disorder (AILD), conditions of immune mediation such as Hashimoto’s thyroiditis, Sjogren’ syndrome and systemic lupus erythematosus [3].

Anaplastic variant: Mammoth, bizarre tumor cells identical to the Reed Sternberg cells with a cohesive and/or a sinusal cell configuration simulating a carcinoma, may characterize the unusual subcategory [3].

Cytoarchitectural modifications

The cytology, architecture or distribution of the lesion may define the themes of DLBCL. The sub-types may result in a misrepresentation,

*Corresponding author: Anubha Bajaj, AB Diagnostics, Hospital and Health Care, West Delhi, Delhi, India, E-mail: anubha.bajaj@gmail.com

Received September 24, 2018; Accepted October 19, 2018; Published October 26, 2018


Copyright: © 2018 Bajaj A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
though the therapeutic protocols or the prognosis may not be influenced [7].

Sclerosis: The DLBCL, particularly the mediastinal (thymic) LBCL may frequently develop considerable sclerosis, identical to a follicular lymphoma. Types I, II and V sub-classes of collagen along with fibronectin may be deposited [3].

Tumor cell spindling: Cellular spindling may be concordant with fibrosis. The DLBCL of the mediastinum and bone may frequently delineate the variation, although it may emerge anywhere in the lymph node. The tumor cells may depict an immune phenotype of the Germinal Centre B (GCB = CD10+ or BCL6+ and MUM1-) maturation.

Myxoid stroma: The abundant component may enunciate the resemblance to a myxoid malignant fibrous histiocytoma or a myxochondrosarcoma [3].

Rosette configurations: Although a preliminary finding in follicular lymphomas, rosettes may be exhibited with DLBCL. The rosettes may be configured of complicated cellular elongations, on ultrastructure.

Filiform cell prolongation: The cellular extensions may be elucidated on ultra-structure. The feature may be elaborated in epithelial carcinomas, mesothelioma or adjunctive neoplasm. DLBCL depicting the prolongations may be denominated an aneumone cell, microvillus, filiform cell, villiform cell or porcune lymphomas [3].

Signet ring features: The appearance of signet ring cells may be frequent in follicular lymphoma and infrequent in DLBCL. The aspect may be identical to a metastatic adenocarcinoma (gastric, breast, ovary) [3].

Sinusal form of dissemination: The tumor cells may be partially or completely confined to the nodal sinuses. The configuration may simulate a metastatic carcinoma, a malignant melanoma or an anaplastic large cell lymphoma.

The inter-follicular pattern of tumor progression: This may be frequent with T cell lymphomas and evidenced with A B cell neoplasm.

Nuclear multi-lobation: Though the feature was initially elucidated with T cell neoplasm, it may be more frequent with a DLBCL [3].

Genetic Elucidation of MYC/BCL2

The MYC protein may be discerned in approximately one third (30-40%) of the DLBCL and 5% of the normal GCB cells. The long arm of the chromosome 8 (8q24) may depict the MYC protein which encodes for the transcription factor and co-ordinates the Ig genes [8]. The MYC protein may be crucial for the cellular metabolism, protein synthesis and differentiation, stem cell regeneration, stressor responses and the coordination of messenger RNA (mRNA) with micro RNA [1,2]. MYC may organize the cell cycle evolution and propagation by partially modifying the transcription of the cyclin-dependent kinases. Paradoxically, the activation of MYC oncprotein may initiate the genomic instability and apoptosis by elucidating the tumor suppressor gene TP53 with the pro-apoptotic protein BIM. As a transcriptional amplifier, MYC may amplify the transcription of genes on the verge of manifestation, instead of initializing the transcription of fresh target genes [1]. Thus the delineation of MYC may enhance the cellular proliferation, manifest genomic instability and augment the existing transcriptional capacity. The BCL2 protein may be discerned in more than half (>50%) the patients with DLBCL and may be absent in the normal GCB cells. Originally detected with follicular lymphoma, BCL2 is located on the chromosome arm of 18q21 [8]. Though BCL2 is a distinctive oncogene, lymphocytes elucidating BCL2 may necessitate cumulative genomic modifications prior to the evolution of overt lymphoma. The principal function of the oncogene BCL2 is to augment the cell survival by prohibiting apoptosis. The specific alteration may be crucial for the MYC induced lymphoma, where a genetic instability along with the destruction of the cellular De-oxy Ribonucleic Acid (DNA) may enhance the stress-induced energy release in order to elucidate the BIM. In the absence of BCL2, BIM may cohere to the effector proteins BAX and BAK for inciting mitochondrial depolarization and cellular mortality [1]. BCL2 expression aggravates the initiation of the lymphoma along with genetic mutations and modifications. BCL2 comprises of one of the six anti-apoptotic proteins (BCL XL, BCL W, MCL1, BFL1, and A1) which may adhere to the BH3 mitochondrial proteins [9]. The BCL2, BCL XL and BCL W oncproteins may be powerful and with the BH3 mitochondrial proteins may elucidate the MYC induced leukaemia. BCL2 may depict adjucitive cellular activity such as autophagy, regulation of calcium and mitochondrial energy, a decline of the reactive oxygen (O2) species and cell cycle modification, the factors which may contribute to the transformation of a lymphoma. Thus BCL2 is a critical anti-apoptotic protein which may synchronize with coexistent oncogenes, particularly the MYC protein, for the progression of the lymphoma. BCL6 is a transcription factor which synergizes the germinal centre response and contains the MYC and BCL2 protein enunciation within the normal GCB cells [1]. De regulation of the BCL2 may hinder the differentiation of post GCB (activated) cells. BCL6 protein expression with BCL6 translocation may be implicated in the DLBCL pathogenesis, though it may not delineate the resistance to therapy (R CHOP).

Molecular Heterogeneity of DLBCL

• The GCB cell variant of DLBCL may delineate immune reactivity for CD10 with expression or translocation of genes such as the BCL6, LMO2, A-MYB, JAW1 with perpetual mutation of the IGH VDJ locus
• The Activated B Cell (ABC DLBCL) category of the diffuse lymphoma may depict reactivity for IRF4+, Cyclin D2, Flip, CD44, IGHM, FOX P1, PRKCB1 with elucidation or genetic mutations such as IGH VDJ
• Genetic aberrations in the GCB variant of DLBCL may be amplifications of the Mir 17-92 and REL genes, a deficit of PTEN and ING1 with gain or amplification of the MDM2 [2]
• The ABC subcategory may display a Trisomy 3 or a 3p chromosomal gain, amplification of NF KB 1 Z, chromosomal gain or amplification of 18q such as BCL2, MALT 1, NFAT 2 with SP113 along with a deficit of CDKN2A/B, INK4A and ARF [2]
• The GCB cell subclass may depict a recombinant BCL2 in 34%, recombinant BCL6 in 10%, a mutated BCL6 in 74%, a TP53 mutation in 30% with an aTP53 deletion in 26% of the DLBCL
• The ABCs variant may depict a mutation of BCL6 in 44%, recombinant BCL6 in 24%, mutation or chromosomal deletion of TP53 in 24% [2]
• Prohibition of the protease function of MALT 1 may be particularly virulent for the ABC DLBCL This specific variant may depict genetic mutations, deletion or methylation in the Cyclin D2, I RF 4, cFLIP, BCL2, CCR7, IkBa and A20 (TNF A IP3) genes. Mutations may also be exemplified in the CARD 11, TNF RSF 11A (RANK), TRAF 5, TRAF 2, MAPK3K7 (TAK1) with recombination of the TNF [2]
• A comprehensive genetic mutation may be enunciated with 51% of the ABC DLBCL lymphomas and 22.7% of the GCB DLBCL variants [2]
A normal GCB cell differentiation may depict an NF KB synergizing the IRF4, BCL6, and BLIMP1+ with the evolution of an IRF4+ mobilized plasma cell. The DLBCL may exhibit a mutation or a translocation of BCL6. The NF KB molecule activates the IRF4 with cellular proliferation with the inactivation of the BLIMP 1 and a mutation or a translocation of the DDR checkpoint, BCL6 with a possible elucidation of the IRF4 activated plasma cell

- DLBCL may inactivate the PROM1 (BLIMP1) through mutation or deletion. The NF KB molecule may mobilize cellular proliferation with the possible activation of IRF4 or BCL6 which may develop the plasma cells [2]

- Practically all the instances of ABC DLBCL variant elucidate the surface Immunoglobulin M (IgM) in the absence of a class switch, the IgM may be preserved on the cell surface. The Class Switch Recombination (CSR) gene may only appear on a non-constructive allele. Enormous genomic deletions may ensue within switch μ regions of a constructive allele. The AID interpolated non-VDJ region somatic hypermutation and translocations integrating the switch region may be elevated, in contrast to the GCB DLBCL variant. Anomalous CSR, genetic coordination or a switch μ deletion may ensure the repetitive failure of the CSR. Amplified somatic hyper mutation or translocations may augment the accessory degradation, leading to the generation of the lymphoma [2]

- The lymphomas may originate from a persistent, active signaling from the B cell receptors (BCR) within the ABC-DLBCL. The SYK dependent tonic B cell receptor signaling may be targeted for therapeutic purposes in the DLBCL [2]

- The DH lymphomas (MYC/BCL2) may be elucidated in adults, where at least half (50%) of the patients may be above 60 years of age. The lymphomas may arise de novo or by virtue of transformation of a preceding follicular lymphoma. Unfavorable clinical features, an inferior Performance Status (PS), an increased International Prognostic Index (IPI), a progressive stage of the disease, an elevated Lactic Dehydrogenase (LDH), extra nodal emergence with bone marrow and/or peripheral blood involvement may characterize the disease

- The genetic profile of the category may be the elucidation of Ig MYC (56%) with a descending involvement as depicted (IgH-IgK-IgL) and specific translocations t (8:14) or complicated ones [t(8;14) t (14:18)]. The non-Ig MYC instances (50%) may exhibit a translocation t(8:9)(q24:p13), 5’ to PAX5 along with mutations of 1p36, 3p25,3q27,4p13,5q13,12p11,13q31. The entire genetic sequence may delineate a complicated karyotype incorporating ≥ 3 translocations [2]

- HGBL DH with a non-molecular Burkitt’s Lymphoma (BL) or an intermediate phenotype may depict a histology of a DLBCL in one third (35%) of the instances or an unclassified B cell lymphoma (BCL u) and/or a Burkitt’s Like Lymphoma (BLL) in the remaining (65%). Majority of the lymphomas may depict a GCB cell immune phenotype (GCB= CD10+ or BCL6+ with MUM1-) along with an elevated Ki 67 proliferation segment. BCL2 elucidation may be intense. The prognosis is poor; the mean Overall Survival (OS) is below 12 months. The chemo-sensitive disease may briskly reoccur [2]

The Methodology of MYC and BCL2 Deregulation

The oncogenes may undergo deregulation within lymphomas in the form of translocations, mutations, copy number variations and transcriptional up-gradation chiefly within the B Cell Receptor (BCR) and NF KB signaling regions, as determined by the sub-category of the lymphoma. The mode of MYC d-regulation may be crucial as it may influence the enunciation of the oncoprotein. An MYC translocation to an Ig locus may elaborate large amounts of MYC mRNA and MYC protein through the Ig promoter induced transcription [10], usually elucidated in 5% of the DLBCL. The MYC translocation may also arise at a non-Ig region in another 5% of individuals afflicted by DLBCL [1]. The method of transcriptional deregulation in these instances are obscure, however, the amount of MYC m RNA and MYC protein generated may be lesser than with the Ig MYC translocations [10]. MYC protein may mutate along with somatic hyper mutations, which may commence with or without translocations. The incidence and category of variant MYC mutations within DLBCL may be of the magnitude of 5%-33% [11]. The gain-of-function MYC mutants (such as T58 or F138) may be discerned in <1% of the DLBCL. T 58 mutations may prevent the MYC m RNA from deterioration, causing an elevation in the MYC protein. The T58 mutations may also augment the cellular proliferation and prohibit apoptosis on account of the decline of the activating BIM [1]. In contrast, the majority of the non-T58 or F138 MYC variants along with the polymorphisms N1 1S may reduce the manifestation of MYC protein within the DLBCL [11]. These variants may also suppress cellular apoptosis in conditions of metabolic stress, though they may not be capable of inducing cellular proliferation [1]. The MYC gene may amplify in 8%-20% of the DLBCL. However, the genetic amplification may not enhance the elucidation of the MYC protein or result in a poor outcome. Signalling networks such as the B Cell Receptor (BCR) and the NF KB may amplify the MYC transcription via direct and indirect coordination at the MYC promoter. The technique of BCL2 deregulation may be identical to the MYC protein, though BCL2 translocation may essentially arise due to abnormal variable diversity joining recombination of the Ig gene, interpolated by the RAG 1/2 within the bone marrow [1]. BCL2 oncoprotein may be mutated in an estimated 68% of the GCB DLBCL and 6% of the ABC DLBCL. The BCL2 mutation may be concomitant with the BCL2 translocation and the BCL2 protein expression. The BH3 domains may be excluded, as they provide the site of adhesion of the BH3 mimics such as Venetoclax and may be required for the anti-apoptotic activity (Figures 1-14) [1].

Genetics of DE DLBCL

The dual expression of MYC and BCL2 proteins in the DE DLBCL may not specify a characteristic tumor morphology although it may be a biomarker of an unfavorable prognosis [7,12]. Co-expression of the proteins (MYC and BCL2) may be pathogenic and may appear with the initial diagnosis along with the tumor recurrence. Subsequent to the initial institution of therapy (CHOP-cyclophosphamide, doxorubicin, vincristine, prednisone), an ineffectual response to intense chemotherapeutic induction regimens, salvage chemotherapy, Autologous Stem Cell Transplant (ASCT) and the contemporary histone de-acetylase inhibitor panobinostat may be elucidated [1]. BCL2 and MYC protein elucidation in the DE DLBCL may define a cumulative genomic modification which may induce an over expression within the B cell receptor (BCR) and the NF KB signaling zones in the ABC variant and translocation in the GCB DLBCL. Coordinated therapy of the BCR signaling mechanics and the BCL2 molecule may be efficacious particularly with the ABC DE DLBCL, though the therapeutic benefit may be missing in the GCB DE DLBCL or in individuals with Ig translocations [1]. MYC translocations may occur in the DLBCL in the absence of BCL2 translocations. Nevertheless, a
HGBL DH and DE DLBCL with concomitant Ig MYC translocations and elevated MYC and BCL2 may delineate the poorest prognosis. The HGBL DH generally are uniform, with the MYC and BCL2 transcription being coordinated through adjunctive genes. The clinical outcomes may vary due to the continual genetic mutations, the reduced elucidation of MYC and BCL2 and the appearance of TP53 mutations with non-Ig MYC coordinates [1].
Disease Characteristics

The majority (95%) of the DH lymphomas may arise as DLBCL or as HGBCL with features intermediate with DLBCL and BL (previously classified as BL unclassifiable (BL u)), currently as HGBCL NOS. A histological conversion of an indolent lymphoma or a contemporary presentation or infrequently as an Acute Lymphoblastic Leukaemia (ALL) or a Follicular Lymphoma (FL) may be exemplified. An Ig MYC translocation may co-exist with a pleomorphic, variable cytology of a disseminated disease with an unfavorable outcome [1,2]. The determination of the HGBCL DH may be debatable. The exclusive
cytogenetic analysis may be expensive, though beneficial for the concerned individuals. A fluorescent in situ hybridization (FISH) may be advantageous for preliminary screening. A regular in situ hybridization (FISH) analysis of the DLBCL may segregate the low-risk individuals. High-risk patients may elucidate leucocytosis, disease appearance within the Central Nervous System (CNS), elevation of LDH values to (>3) beyond three times the normal and an advanced stage disease [1,2]. DE DLBCL lacking the MYC and BCL2 translocations may also be clinically aggressive with an elevated IPI. The recurrence of the CNS disease at 2 years may be roughly 10% [6,7]. A comprehensive Cerebrospinal Fluid (CSF) assessment at the initial presentation of the DE DLBCL may be mandated.

Fluorescent in situ Hybridization

The investigation (FISH) may be required in the suspected BL, lymphomas with MYC translocations in >20% cells such as the High-Grade B Cell Non-Specific (HGBCL NOS) variant, plasmablastic lymphoma, and transformation of a previous follicular lymphoma [8,13]. An in situ hybridization (FISH) may be mandated in all possible instances of DLBCL in order to analyze the HGBL DH variant. An interphase hybridization (FISH) may be efficacious in discerning the non-Ig MYC translocation. Fusion probes employing the MYC, IgH, IgK and Ig λ genes may be accomplished for adjuvant testing [1]. An immune histochemical evaluation may be beneficial in recognizing instances with mandatory in situ hybridization [8]. Ki 67 may be inconstantly expressed in the HGBL DH along with ineffectual staining intensity and tumor content. A conventional assessment of BCL2 gene may be required, though an MYC evaluation may not be customary. Applying the cell of origin with the concordance of MYC and BCL2 may be advantageous to assess instances of unsuccessful therapeutic outcomes in the DLBCL, where an in situ hybridization may be inconvenient to perform [14]. Analysis of lymphomas with a GCB phenotype may ensure the reduction of instances of in situ hybridization (FISH) by half (50%) (Tables 1 and 2) [15].

Therapeutic Protocols

The optimal chemotherapeutic protocols of the HGBL DH and DE DLBCL have not been determined. Aggressive chemotherapeutic induction programmes may delineate a favorable Progression Free Survival (PFS). As the patients are elderly and infirm, an intense chemotherapy may be unsuitable. The employment of contemporary, targeted molecules may be advantageous. The initiation of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R CHOP) may delineate a poor response in the HGBL DH variant [1]. The extensive chemotherapies may depict an increased PFS of 22 months, in contrast to the estimated figure of 8 months with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R CHOP), though the OS may not be impacted [1]. Rituximab with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R EPOCH) may display an improved Complete Response Rate (CRR), contrary to the rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R CHOP) regime. A curative rate of 40%
may be exhibited with various therapies [1,2]. A decreased toxicity may be demonstrated, in contrast to the intensive, high dose treatment protocols, thus may be an advantageous therapeutic induction modality. The individuals may exhibit a superior PS. Comprehensive cytogenetic evaluation of HGBCL may segregate the low-risk HGBL DH which may be managed singularly with rituximab along with cyclophosphamide, doxorubicin, vincristine, and prednisone (R CHOP). ASCIT and/or an extensive chemotherapy induction protocol may not be adequate for the high-risk persons [1]. Collaborative trials for Relapse or Aggressive Lymphomas (CORAL) with elucidated MYC translocation may indicate an inadequate response to the salvage chemotherapy and the ASCIT in individuals delineating Relapsed and Refractory DLBCL (or DLBCL). Such instances may depict a 3 year PFS of 17-19%. A majority (81%) of DLBCL may elucidate the BCL2 protein [1]. Although patients of the DE DLBCL and HGBL DH may exemplify an inferior prognosis, individuals with synergic, high grade, relapsing lymphomas (DE DLBCL or HGBL DH or DLBCL) may display early reoccurrence in a short span following ASCIT. An estimated one third (20-30%) of the HGBL DH may exhibit a refractory disease in spite of an extensive initiating chemotheraphy. Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R CHOP) may be remedial in the majority (>90%) of the DLBCL with solitary MYC translocation in the absence of BCL2 protein expression or translocation [16]. Containing the BCL2 protein may be beneficial. The BH3 analogue ventoclax, designated as the ABT 199, is a specific inhibitor of BCL2. The combination of ventoclax with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and rituximab or obinutuzumab may exhibit a Comprehensive Response Rate (CRR) of 91% [1]. An anti-apoptotic protein sensitization may be a pre-requisite (MCL1 or BCL XL) for instances of ventoclax resistance. Determining the MYC protein may be advantageous as it displays a brief half-life (4 hours) in contrast to the BCL2 (24 hours) [1]. Prohibiting translocation or transcription of the proteins may also be efficacious during therapy of Eu-MYC lymphomas. Targeted therapy for DE DLBCL or HGBL DH with immune modulating agents such as lenalidomide may be useful in CNS reoccurrences [16]. The ABC subtype of DLBCL may respond to the BTK inhibitor ibrutinib which produces MYC and BCL2 proteins via the BCR signalling. Agents such as bortezomib along with ibrutinib and ventoclax may be employed in the clinical trials of DLBCL on account of the noxious elements such as the Tumour Lysis Syndrome (TLS) [1,2]. Administration of drug combinations of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R CHOP) with lenalidomide, bortezomib and ibrutinib may be followed up with successive biopsies of the tumour tissue in order to determine if the MYC and BCL2 co-expression or translocation may be efficacious as biomarkers of therapeutic response [1]. The comprehensive 5 year PFS for all patients subjected to R CHOP therapy may be at an estimated 80%, with moderate variations within the high risk, intermediate risk or low risk groups as elucidated with the IPI [17].

References